X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs PFIZER - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS PFIZER NOVARTIS/
PFIZER
 
P/E (TTM) x 392.8 29.2 1,345.4% View Chart
P/BV x 19.3 4.6 416.6% View Chart
Dividend Yield % 1.5 0.7 213.8%  

Financials

 NOVARTIS   PFIZER
EQUITY SHARE DATA
    NOVARTIS
Mar-16
PFIZER
Mar-16
NOVARTIS/
PFIZER
5-Yr Chart
Click to enlarge
High Rs9822,724 36.0%   
Low Rs5561,611 34.5%   
Sales per share (Unadj.) Rs252.9440.9 57.4%  
Earnings per share (Unadj.) Rs62.148.7 127.6%  
Cash flow per share (Unadj.) Rs63.375.8 83.5%  
Dividends per share (Unadj.) Rs10.0015.00 66.7%  
Dividend yield (eoy) %1.30.7 187.9%  
Book value per share (Unadj.) Rs363.6462.9 78.5%  
Shares outstanding (eoy) m31.9645.75 69.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.04.9 61.9%   
Avg P/E ratio x12.444.5 27.8%  
P/CF ratio (eoy) x12.228.6 42.5%  
Price / Book Value ratio x2.14.7 45.2%  
Dividend payout %16.130.8 52.2%   
Avg Mkt Cap Rs m24,58099,163 24.8%   
No. of employees `0000.82.9 26.0%   
Total wages/salary Rs m1,8012,758 65.3%   
Avg. sales/employee Rs Th10,748.96,981.7 154.0%   
Avg. wages/employee Rs Th2,395.2954.5 250.9%   
Avg. net profit/employee Rs Th2,641.1771.1 342.5%   
INCOME DATA
Net Sales Rs m8,08320,170 40.1%  
Other income Rs m829857 96.7%   
Total revenues Rs m8,91321,028 42.4%   
Gross profit Rs m2344,310 5.4%  
Depreciation Rs m371,239 3.0%   
Interest Rs m25 34.6%   
Profit before tax Rs m1,0253,923 26.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,69699 1,715.7%   
Tax Rs m7521,794 41.9%   
Profit after tax Rs m1,9862,228 89.2%  
Gross profit margin %2.921.4 13.6%  
Effective tax rate %73.445.7 160.4%   
Net profit margin %24.611.0 222.5%  
BALANCE SHEET DATA
Current assets Rs m12,67816,299 77.8%   
Current liabilities Rs m2,4337,594 32.0%   
Net working cap to sales %126.743.2 293.7%  
Current ratio x5.22.1 242.8%  
Inventory Days Days3365 50.1%  
Debtors Days Days2226 87.3%  
Net fixed assets Rs m698,622 0.8%   
Share capital Rs m160458 34.9%   
"Free" reserves Rs m11,46020,722 55.3%   
Net worth Rs m11,62121,180 54.9%   
Long term debt Rs m025 0.0%   
Total assets Rs m14,40029,137 49.4%  
Interest coverage x570.5755.5 75.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.7 81.1%   
Return on assets %13.87.7 180.1%  
Return on equity %17.110.5 162.5%  
Return on capital %23.619.0 124.1%  
Exports to sales %0.70.1 1,251.8%   
Imports to sales %18.617.5 106.4%   
Exports (fob) Rs m6012 501.7%   
Imports (cif) Rs m1,5033,526 42.6%   
Fx inflow Rs m18652 360.7%   
Fx outflow Rs m1,821140 1,300.8%   
Net fx Rs m-1,635-88 1,850.4%   
CASH FLOW
From Operations Rs m2,5313,436 73.7%  
From Investments Rs m-8,270-6,991 118.3%  
From Financial Activity Rs m-386-619 62.3%  
Net Cashflow Rs m-6,125-4,174 146.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 63.9 117.4%  
Indian inst/Mut Fund % 2.0 7.5 26.7%  
FIIs % 1.6 4.9 32.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 23.7 90.7%  
Shareholders   41,647 85,207 48.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   STRIDES SHASUN LTD  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  ELDER PHARMA  

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Sensex Touching Record Highs, Rally in Banking Stocks and Key Stocks in Action Today(Pre-Open)

BSE Sensex is on a roll. The index touched a record high of 35,000 on Wednesday and further inched upwards to end yesterday's trade at a level of 35,260.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jan 18, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS